中国医学创新
中國醫學創新
중국의학창신
Medical Innovation of China
2015年
30期
17-20
,共4页
徐慧高%吕志玲%王平%杨建荣%徐泽东%耿强%王思明
徐慧高%呂誌玲%王平%楊建榮%徐澤東%耿彊%王思明
서혜고%려지령%왕평%양건영%서택동%경강%왕사명
血管瘤%聚桂醇%平阳霉素%疗效%并发症
血管瘤%聚桂醇%平暘黴素%療效%併髮癥
혈관류%취계순%평양매소%료효%병발증
Hemangioma%Lauromacrogol%Pingyangmycin%Efficacy%Complication
目的:研究聚桂醇与平阳霉素、地塞米松在治疗颌面部血管瘤方面的临床疗效与并发症方面的差异.方法:将108例颌面部血管瘤患者随机分为聚桂醇组和平阳霉素组,分别采用聚桂醇和平阳霉素、地塞米松进行注射治疗,比较两组的疗效和并发症.结果:聚桂醇组疗效和并发症均优于平阳霉素组.结论:聚桂醇疗效优于平阳霉素,并发症低于平阳霉素,作为硬化剂,是治疗血管瘤的有效药物,值得推广.
目的:研究聚桂醇與平暘黴素、地塞米鬆在治療頜麵部血管瘤方麵的臨床療效與併髮癥方麵的差異.方法:將108例頜麵部血管瘤患者隨機分為聚桂醇組和平暘黴素組,分彆採用聚桂醇和平暘黴素、地塞米鬆進行註射治療,比較兩組的療效和併髮癥.結果:聚桂醇組療效和併髮癥均優于平暘黴素組.結論:聚桂醇療效優于平暘黴素,併髮癥低于平暘黴素,作為硬化劑,是治療血管瘤的有效藥物,值得推廣.
목적:연구취계순여평양매소、지새미송재치료합면부혈관류방면적림상료효여병발증방면적차이.방법:장108례합면부혈관류환자수궤분위취계순조화평양매소조,분별채용취계순화평양매소、지새미송진행주사치료,비교량조적료효화병발증.결과:취계순조료효화병발증균우우평양매소조.결론:취계순료효우우평양매소,병발증저우평양매소,작위경화제,시치료혈관류적유효약물,치득추엄.
Objective:To study the differences of clinical efficacy and complications of lauromacrogol and pingyangmycin,dexamethasone in the treatment of maxillofacial hemangioma.Method:108 cases of maxillofacial hemangioma were randomly divided into lauromacrogol group and Pingyang mycin group,they were treated with lauromacrogol and Pingyang mycin injection,dexamethasone treatment respectively. Then the clinical efficacy and complications of two groups were compared.Result:The curative effect and complication of Lauromacrogol group were better than those of Pingyangmycin group.Conclusion:The curative effect and complications of Lauromacrogol are better than those of Pingyangmycin, it is an effective drug for the treatment of hemangioma,is worthy of promotion.
